2-Deoxy-D-glucose: Metabolic Checkpoint Targeting in Tumor and Viral Research

Introduction

Metabolic rewiring is a hallmark of cancer and viral infections, underpinning the survival and adaptability of malignant and infected cells. 2-Deoxy-D-glucose (2-DG), a glucose analog, has emerged as a premier research tool and therapeutic candidate for targeting glycolytic flux, modulating metabolic oxidative stress, and exploring the immunometabolic landscape of disease. While a breadth of literature exists on the utility of 2-DG as a glycolysis inhibitor, this article delves into its multifaceted mechanisms—particularly its role in targeting metabolic checkpoints within the tumor microenvironment (TME) and during viral replication. We will synthesize the latest findings, including novel insights into AMP kinase (AMPK) and PI3K/Akt/mTOR signaling modulation, and clarify how 2-DG sets itself apart from conventional metabolic inhibitors.

Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

Disrupting Glycolysis and ATP Synthesis

2-Deoxy-D-glucose (2-DG) is a structural analog of glucose, differing by the absence of a hydroxyl group at the 2' position. Upon cellular entry via glucose transporters, 2-DG is phosphorylated by hexokinase to 2-DG-6-phosphate, which cannot proceed through glycolysis. This competitive inhibition leads to the accumulation of glycolytic intermediates, suppresses glycolytic flux, and results in ATP synthesis disruption. The subsequent drop in ATP levels induces metabolic oxidative stress, rendering cells vulnerable to further insults and impeding their survival, especially under the high metabolic demands of cancer proliferation or viral replication.

Induction of Metabolic Oxidative Stress

By stalling glycolysis, 2-DG forces cells to rely on less efficient energy production pathways, increasing mitochondrial reactive oxygen species (ROS) and oxidative stress. This metabolic pressure sensitizes tumor cells and infected cells to chemotherapeutics and immune-mediated killing. Notably, 2-DG has demonstrated potent cytotoxicity in KIT-positive gastrointestinal stromal tumor (GIST) cell lines, with IC₅₀ values in the sub-micromolar range, and effectively slows tumor growth when combined with Adriamycin or Paclitaxel in animal models.

Modulation of the PI3K/Akt/mTOR Signaling Pathway

Beyond direct glycolysis inhibition, 2-DG indirectly modulates the PI3K/Akt/mTOR pathway—a critical metabolic checkpoint governing cell proliferation, survival, and immune evasion. By reducing glycolytic intermediates and ATP, 2-DG dampens mTORC1 signaling, which is essential for anabolic metabolism and protein synthesis. This effect aligns with recent discoveries showing how metabolic checkpoints, such as lysosomal cholesterol/oxysterol sensing and AMPK activation, drive immunosuppressive macrophage programming (see Xiao et al., 2024).

2-DG as a Metabolic Checkpoint Modulator in the Tumor Microenvironment

Targeting Immunosuppressive Macrophages and Tumor-Associated Metabolism

While existing resources primarily emphasize the direct anti-tumor and antiviral actions of 2-DG, a critical and emerging application is its role in reprogramming the tumor immune landscape. Recent work (Xiao et al., 2024) has elucidated how metabolic reprogramming of tumor-associated macrophages (TAMs) via cholesterol-25-hydroxylase (CH25H) and lysosomal 25-hydroxycholesterol (25HC) accumulation activates AMPKα and suppresses mTORC1, thereby orchestrating immunosuppressive phenotypes. 2-DG, through glycolysis inhibition and mTORC1 dampening, mimics aspects of this metabolic checkpoint, potentially shifting TAMs from a pro-tumorigenic to a pro-inflammatory state.

Unlike traditional chemotherapy, 2-DG's ability to modulate the broader immunometabolic axis—intersecting with AMPK/mTOR/STAT6 signaling—offers a new avenue for sensitizing tumors to immunotherapy. For instance, the referenced paper demonstrates that targeting CH25H can convert 'cold' tumors (low T cell infiltration) into 'hot' tumors (high T cell infiltration), improving anti-PD-1 checkpoint efficacy. Integration of 2-DG into such strategies may further potentiate these anti-tumor immune responses by disrupting the metabolic crosstalk that supports immune evasion.

Comparative Perspective: Building Upon Prior Insights

While "2-Deoxy-D-glucose: Unveiling Precision Metabolic Control" provides a comprehensive overview of 2-DG's role in precision manipulation of tumor and immune cell metabolism, this article advances the conversation by focusing on the integration of 2-DG with next-generation immunometabolic strategies. We uniquely explore 2-DG's synergies with metabolic checkpoint inhibitors and immune reprogramming, grounded in the mechanistic insights from the latest CH25H-AMPK-mTORC1 axis research. This deepens the translational potential of 2-DG beyond its established cytotoxic and metabolic stress-inducing roles.

Advanced Applications of 2-DG in Cancer and Viral Research

KIT-positive Gastrointestinal Stromal Tumor (GIST) and Non-Small Cell Lung Cancer (NSCLC)

2-DG has shown pronounced efficacy in targeting KIT-positive GIST, a tumor type highly dependent on glycolytic metabolism. Experimental data indicate cytotoxicity at low micromolar concentrations (IC₅₀ values of 0.5 μM for GIST882 and 2.5 μM for GIST430), highlighting its potency as a glycolysis inhibition tool in cancer research. In NSCLC, 2-DG enhances the activity of established chemotherapeutics—such as Adriamycin and Paclitaxel—by inducing metabolic oxidative stress and impairing ATP generation, leading to reduced tumor growth in xenograft models.

These findings position 2-DG as a valuable adjunct in combination regimens, particularly for overcoming resistance associated with metabolic plasticity in tumors. Its ability to modulate both cancer cell-intrinsic metabolism and the immunosuppressive TME marks a significant advancement over traditional cytotoxic agents.

Viral Replication Inhibition

Beyond oncology, 2-DG is gaining traction in antiviral research as a metabolic pathway research tool. By interfering with glycolysis and early protein synthesis, 2-DG impairs viral replication cycles and inhibits the expression of viral proteins, as demonstrated in porcine epidemic diarrhea virus (PEDV) models using Vero cells. This broad-spectrum mechanism is particularly relevant for viruses that hijack host glucose metabolism to fuel replication, offering a metabolic bottleneck that can be exploited therapeutically.

Protocol Considerations and Solubility

2-DG is highly soluble in water (≥105 mg/mL), moderately soluble in DMSO (≥8.2 mg/mL), and can be dissolved in ethanol (≥2.37 mg/mL) with warming and ultrasonic treatment. Standard experimental protocols involve treatment concentrations of 5–10 mM for 24 hours, but optimization may be required based on cell type and research objective. Storage at -20°C is recommended, with avoidance of long-term solution storage to preserve compound integrity.

Comparative Analysis with Alternative Methods

Several articles, such as "Precision Glycolysis Inhibitor for Translational Research", offer workflow optimization and troubleshooting tips for 2-DG use, while "Advanced Glycolysis Inhibition for Cancer and Viral Research" highlights protocol enhancements. In contrast, this article contextualizes 2-DG within the broader immunometabolic checkpoint paradigm, emphasizing its dual role as a glycolytic inhibitor and a modulator of immune cell fate. By integrating insights from the latest CH25H-AMPK-mTORC1-STAT6 research, we move beyond standard application guides to position 2-DG as a strategic tool for experimental designs targeting metabolic-immune crosstalk.

Distinctive Value: From Metabolic Inhibition to Immunometabolic Reprogramming

Competitive glycolysis inhibitors (e.g., lonidamine, 3-bromopyruvate) primarily target energy metabolism within cancer cells. However, 2-DG's ability to disrupt both metabolic and immune signaling—particularly in the context of PI3K/Akt/mTOR and AMPK/STAT6 pathways—makes it uniquely suited for advanced studies in glycolysis inhibition in cancer research and antiviral therapy. This dual action supports not only direct cytotoxicity but also the reprogramming of the TME and viral-host interactions, which is not addressed by most alternative metabolic inhibitors.

Future Directions: Integrating 2-DG in Next-Generation Immunometabolic Therapies

The convergence of metabolic pathway research and immunotherapy opens new frontiers for 2-DG. Ongoing studies are evaluating its synergy with checkpoint inhibitors, such as anti-PD-1, and its ability to disrupt metabolic checkpoints governing macrophage polarization. Given the recent demonstration that targeting CH25H and lysosomal 25HC can reshape the TME to favor T cell infiltration and enhance immunotherapy (see Xiao et al., 2024), combining 2-DG with agents that modulate oxysterol metabolism or AMPK/mTOR signaling could unlock superior anti-tumor responses.

Furthermore, the metabolic plasticity of both cancer cells and viruses suggests that dual-targeting strategies—using 2-DG alongside pathway-selective inhibitors or immune modulators—may offer durable disease control. As the mechanistic landscape evolves, 2-DG remains a central tool for dissecting the interplay between metabolism, immune evasion, and therapeutic resistance.

Conclusion

2-Deoxy-D-glucose (2-DG) stands at the nexus of metabolic and immune regulation, offering a unique platform for the study and modulation of glycolytic flux, ATP synthesis disruption, and metabolic oxidative stress induction. Its ability to modulate the PI3K/Akt/mTOR and AMPK/STAT6 pathways positions it as a next-generation metabolic pathway research tool for both cancer and virology. By integrating mechanistic insights from recent immunometabolic studies and extending beyond standard glycolysis inhibition, 2-DG empowers researchers to target metabolic checkpoints, reprogram the tumor microenvironment, and enhance the efficacy of immunotherapies.

For investigators seeking to expand the boundaries of translational research, 2-Deoxy-D-glucose (2-DG) (B1027) offers unparalleled versatility—supporting studies ranging from KIT-positive gastrointestinal stromal tumor treatment and non-small cell lung cancer metabolism to viral replication inhibition and metabolic checkpoint modulation. As the field advances, the role of 2-DG as both a glycolysis inhibitor and immunometabolic modulator is poised to grow, driving innovation in cancer and infectious disease research.